pentobarbital will minimize the extent or impact of elbasvir/grazoprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic impact of elbasvir/grazoprevir may very well be decreased if coadministered with robust CYP3A inducers and is also for that reason contraindicated.pentobarbital will lower the extent or